


Improved therapeutic delivery targeting clinically relevant orthotopic human pancreatic tumors in pig models using ultrasound-induced cavitation

Khan Mohammad Imran^{1,2}, Benjamin Tintera², Holly A. Morrison², Juselyn D. Tupik², Margaret A. Nagai-Singer², Hannah Ivester¹, McAlister Council-Troche², Michael Edwards³, Sheryl Coutermarsh-Ott², Christopher Byron⁴, Sherrie Clark-Deener⁴, Kyungjun Uh⁵, Kiho Lee⁵ Paul Boulos⁶, Cliff Rowe⁶, Christian Coviello⁶, Irving C. Allen^{1,2*}

Supplemental data





Supplemental Figure S1. Genotyping of piglets carrying modified *RAG2* and *IL2RG* genes.

Analyte	Parent Ion (amu)	Product Ion (amu)	Cone Energy (V)	Collision Energy (eV)	Quant/Qual Transition
Gemcitabine	264.0 [M+H] ⁺	111.9	38	16	Quantifier
	264.0 [M+H] ⁺	87.0	38	28	Qualifier 1
¹³ C, ¹⁵ N ₂ - Gemcitabine (IS)	267.1 [M+H] ⁺	115.0	42	20	Quantifier
Paclitaxel	854.4 [M+H] ⁺	286.1	26	20	Quantifier
	854.4 [M+H] ⁺	569.2	26	13	Qualifier 1
Paclitaxel-d5 (IS)	859.9 [M+H] ⁺	291.2	26	20	Quantifier
	859.9 [M+H] ⁺	509.2	26	16	Qualifier 1



Supplemental figure S2. MRM transitions and specific mass spectrometry tuning parameters for the quantification of gemcitabine and paclitaxel.

Supplemental Figure S3. SonoTran-mediated cavitation treatment of pancreatic tumors.

A) Target treatment in pancreas tissue – First Pig Treated



B) Target treatment in pancreas tissue – 2nd Pig Treated



C) Target treatment in pancreas tissue – 3rd Pig Treated

